Literature DB >> 31383996

Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy.

Xiujian Wang1,2,3,4, Yongxian Hu1,2,3,4, Xiao Liu5, Jian Yu1,2,3,4, Pengfei Xu6, Guoqing Wei1,2,3,4, Chao Jin6, Wenjun Wu1,2,3,4, Huarui Fu1,2,3,4, Lijuan Ding1,2,3,4, Fang Ni1,2,3,4, Hao Zhang1,2,3,4, Zuyu Liang1,2,3,4, Binsheng Wang1,2,3,4, Xiaoqing Li1,2,3,4, Cong Wei1,2,3,4, Yunyun Deng6, Jimin Shi1,2,3,4, Lei Xiao7, Zhao Wu7, Tao Sun8, He Huang9,10,11,12.   

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of CAR-T therapy on host immune system has not been well elucidated. Thus, We applied high-throughput T cell receptor β chain sequencing to track the dynamic change of T-cell repertoire induced by CAR-T therapy in B-cell ALL patients. Six Chinese patients achieving complete remission were under observation, whose blood samples, bone marrow samples and infused CAR-T samples were collected at serial time points before and after CAR-T therapy. We observed decreased TCR diversity and increased clonality of T-cell repertoire in both peripheral blood and bone marrow after CAR-T administration. The persistent T cell clones in blood and bone marrow expanded following leukemic cell destruction and were barely detected in CAR T-cell pool. For the first time, our results demonstrated CAR-T therapy could stimulate the clonal proliferation of CAR-negative T cells in patients. Considering other groups' animal results indicating that CAR-T therapy could facilitate the proliferation of tumor antigen-specific T cells and that the emergence of these T cell clones followed the destruction of leukemic cells, they are most likely tumor antigen-specific.

Entities:  

Year:  2019        PMID: 31383996     DOI: 10.1038/s41409-019-0625-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.

Authors:  Federico Simonetta; Juliane K Lohmeyer; Toshihito Hirai; Kristina Maas-Bauer; Maite Alvarez; Arielle S Wenokur; Jeanette Baker; Amin Aalipour; Xuhuai Ji; Samuel Haile; Crystal L Mackall; Robert S Negrin
Journal:  Clin Cancer Res       Date:  2021-08-10       Impact factor: 12.531

2.  Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects.

Authors:  Dangsheng Xiao; Ju Wang; Zhitao Chen; Xiuyuan Jin; Yirui Xie; Dong Yan; Jiezuan Yang
Journal:  BMC Infect Dis       Date:  2021-01-23       Impact factor: 3.090

3.  Altered T-Cell Receptor β-Chain and Lactate Dehydrogenase Are Associated With the Immune Pathogenesis of Biliary Atresia.

Authors:  Jing Ye; Dengming Lai; Dan Cao; Linhua Tan; Lei Hu; Hua Zha; Jiezuan Yang; Qiang Shu
Journal:  Front Med (Lausanne)       Date:  2021-12-24

4.  The Relationship Between Convergent IGH Signatures and Severity of COVID-19 Patients by Next-Generation Sequencing of B-Cell Repertoire.

Authors:  Hongliu Cai; Juan Hu; Lingtong Huang; Chunhua Gao; Mi Xu; Yuzhi Gao; Tao Sun; Xueling Fang
Journal:  Front Microbiol       Date:  2022-02-09       Impact factor: 5.640

5.  Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non-Small-Cell Lung Cancer Patients Treated With the Anti-PD-L1 Antibody.

Authors:  Jin Sheng; Huadi Wang; Xiao Liu; Yunyun Deng; Yingying Yu; Pengfei Xu; Jiawei Shou; Hong Pan; Hongsen Li; Xiaoyun Zhou; Weidong Han; Tao Sun; Hongming Pan; Yong Fang
Journal:  Front Mol Biosci       Date:  2021-07-09

6.  The methods and advances of adaptive immune receptors repertoire sequencing.

Authors:  Hongmei Liu; Wenjing Pan; Congli Tang; Yujie Tang; Haijing Wu; Akihiko Yoshimura; Yan Deng; Nongyue He; Song Li
Journal:  Theranostics       Date:  2021-08-19       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.